IGF-DES potential benefits and areas of research

IGF-DES has no established benefit in humans. What it has is a well-documented in-vitro potency figure and an unusually clear statement about its own evidence gap. The foundational review of the molecule concluded that des(1-3)IGF-I is generally about 10-fold more potent than IGF-I at stimulating hypertrophy and proliferation of cultured cells, that the increased potency is retained in part when given in vivo, and that "clinical opportunities for des(1-3)IGF-I have not yet been evaluated" (PMID 8930132).

That last clause was written about a molecule described in the mid-1990s. It has not been superseded by human trials since.

Unlike IGF-1 LR3, which is a designed laboratory construct, des(1-3)IGF-I occurs naturally. It is IGF-I missing the N-terminal tripeptide Gly-Pro-Glu, and it has been isolated from bovine colostrum, human brain, and porcine uterus — probably arising from post-translational cleavage of IGF-I rather than from a separate gene (PMID 8930132).

The mechanism of its potency is specific and worth stating precisely: removing those three residues eliminates the glutamate at position 3, and it is the absence of that single residue that drives the much-reduced binding to IGF-binding proteins. This is the same lever LR3 pulls with an arginine substitution at the same position — DES achieves it by deletion rather than substitution.

The "10-fold more potent" figure circulates widely and is real, but its scope is narrow. It describes stimulation of hypertrophy and proliferation in cultured cells, where no IGF-binding proteins are present to buffer either molecule and the comparison isolates receptor engagement plus binding behaviour in a dish.

In whole animals, the review reports that the increased potency is retained only in part, with selective anabolic effects "particularly evident in gut tissues" — an observation that prompted speculation about catabolic states and inflammatory bowel disease as possible applications rather than about skeletal muscle.

The comparative animal pharmacology bears out the potency ranking on a different endpoint. In pigs and marmosets, des(1-3)IGF-I sat at the top of the hypoglycemic potency order (IGF-I < long-IGF-I < R3IGF-I ≈ LR3IGF-I < des(1-3)IGF-I), and the binding-resistant variants as a group produced roughly 4- to 8-fold greater cumulative glucose suppression than native IGF-I over four hours (PMID 9415072). The most potent variant in that ranking was DES.

The two analogs are frequently discussed as a pair, and the contrast is genuine:

• Origin — DES is a naturally occurring cleavage product; LR3 is an engineered construct with an added N-terminal extension.
• Potency — DES ranked highest of the variants tested for glucose lowering; LR3 sat alongside R3IGF-I a step below.
• Duration — LR3's added extension was designed for prolonged systemic action; DES is generally described as shorter-acting, which is the basis of the claim that it works locally.

The "local action" framing deserves a caveat. It is an inference from a short half-life, not a demonstrated tissue-targeting property, and no published human study shows that injecting DES near a muscle confines its effects there. The same animal data show DES lowering systemic plasma glucose more than any other variant tested — which is, definitionally, a systemic effect.

IGF-DES is not approved for human use in any jurisdiction and is sold as a research chemical. The approved IGF-1 medicine is mecasermin (Increlex), a full-length recombinant IGF-1 licensed only for growth failure in children with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies, and its label states it is not a substitute for GH in approved GH indications (Increlex label, DailyMed). That drug — the regulated, binding-protein-sensitive one — carries a meal-timing requirement and a hypoglycemic-seizure warning. DES is the more potent molecule with none of the oversight. See the side-effects page.